GlassScriptPhysician profile
Michael J Dallolio
NPI 1972531226
$1,877.32
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $329 · 2021: $751 · 2022: $251.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $451.71 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $391.78 | 2019-2022 | |
| Alkermes, INC. | $313.63 | 2019-2022 | |
| Lundbeck LLC | $288.24 | 2019-2022 | |
| Abbvie INC. | $97.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $72.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.51 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.30 | 2022 | |
| Eisai INC. | $35.44 | 2021 | |
| Jazz Pharmaceuticals INC. | $32.36 | 2019 | |
| Orexo US, INC. | $24.71 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.68 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.41 | 2021 | |
| Neurocrine Biosciences, INC. | $15.19 | 2019 | |
| Acadia Pharmaceuticals INC | $14.29 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.34 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dallolio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.